VIDEO-AUDIO MEDIA
Add like
Add dislike
Add to saved papers

Evaluation of treatments for Bartholin's cyst or abscess: a systematic review.

BACKGROUND: No consensus on the management of symptomatic cysts or abscesses of the Bartholin's gland exists.

OBJECTIVES: To assess the effectiveness and safety of surgical interventions for a symptomatic Bartholin's cyst or abscess.

SEARCH STRATEGY: We searched bibliographical databases from inception to April 2019.

SELECTION CRITERIA: Randomised trials evaluating a surgical intervention for the treatment of a symptomatic Bartholin's cyst or abscess.

DATA COLLECTION AND ANALYSIS: Eight trials, reporting data from 699 women, were included. Study characteristics and methodological quality were recorded for each trial. Summary estimates were calculated using random-effects methods.

MAIN RESULTS: When considering the recurrence of a symptomatic Bartholin's cyst or abscess, the evidence was consistent with notable effects in either direction (risk ratio [RR] 0.76; 95% confidence interval [CI] 0.41-1.40) when comparing marsupialisation with incision, drainage and insertion of a Word catheter. Limited inference could be made when comparing marsupialisation with incision, drainage and silver nitrate insertion (RR 1.00; 95% CI 0.57-1.75), and incision, drainage and cavity closure (RR 0.25; 95% CI 0.01-4.89). There was limited reporting of secondary outcomes, including haematoma, infectious morbidity and persistent dyspareunia.

CONCLUSIONS: Current randomised trial evidence does not support the use of any single surgical intervention for the treatment of a symptomatic cyst or abscess of the Bartholin's gland.

PROSPECTIVE REGISTRATION: PROSPERO: International Prospective Register of Systematic Reviews; CRD42018088553.

TWEETABLE ABSTRACT: Further research is needed to identify an effective treatment for #Bartholin's cyst or abscess. @jamesmnduffy.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app